nitpicker / Shutterstock.com
4 September 2026NewsRegulation & IndustryMarisa Woutersen

G 1/25: EPO settles controversial patent description question

Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Regulation & Industry
19 November 2026   The 2027 US awards in Boston features three new categories recognising AI innovation, in-house IP teams and cross-border patent litigation.
Regulation & Industry
5 November 2026   Things can go “sideways pretty quickly” if the two sides of pharma protection are not communicating with each other, said a senior panel of industry counsel at LSPN Fall.
Regulation & Industry
5 November 2026   From November 1, oral proceedings before a Board of Appeal can be audio-recorded and transcribed using artificial intelligence, but any material generated will be kept internal and will not form part of the file or be made available